Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms
2
조회
0
다운로드
14
인용
0
참고문헌
키워드
초록
Objective: In 2001, the Korean College of Neuropsychopharmacology and the Korean Society for Schizophrenia Research developed the Korean Medication Algorithm Project for Schizophrenia (KMAP-SPR 2001, revised 2006) through a consensus of expert opinion. The present study was carried out to support the second revision of the KMAP-SPR. Methods: Based on clinical guidelines and studies on the treatment of psychotic symptoms in schizophrenia, the Executive committee completed a draft of KMAP-SPR 2019. To obtain an expert consensus, a Review committee of 100 Korean psychiatrists was formed and 69 responded to a 30-item questionnaire. Based on their responses, the KMAP-SPR 2019 was finalized. Results: The revised schizophrenia algorithm now consists of 5 stages. At Stage 1, monotherapy with atypical antipsychotics was recommended by expert reviewers as the first-line strategy. At Stage 2, most reviewers recommended the use of typical or atypical antipsychotic drugs not used at Stage 1. At Stage 3, many reviewers agreed with the administration of clozapine. At Stage 4, a combination of clozapine and other agents such as antipsychotics, mood stabilizers, antidepressants, or electroconvulsive therapy was recommended. At Stage 5, most reviewers recommended combined treatment with an antipsychotic other than clozapine; and a mood stabilizer, antidepressant, or electroconvulsive therapy. At any stage, prescribing long-acting injectable antipsychotics at the discretion of the clinician was recommended. Conclusion: Compared with previous versions, the KMAP-SPR 2019 now recommends using clozapine earlier in treatment- refractory schizophrenia. In addition, the use of long-acting injectable antipsychotics is now considered to be available at any stage.
Abstract
Objective: In 2001, the Korean College of Neuropsychopharmacology and the Korean Society for Schizophrenia Research developed the Korean Medication Algorithm Project for Schizophrenia (KMAP-SPR 2001, revised 2006) through a consensus of expert opinion. The present study was carried out to support the second revision of the KMAP-SPR. Methods: Based on clinical guidelines and studies on the treatment of psychotic symptoms in schizophrenia, the Executive committee completed a draft of KMAP-SPR 2019. To obtain an expert consensus, a Review committee of 100 Korean psychiatrists was formed and 69 responded to a 30-item questionnaire. Based on their responses, the KMAP-SPR 2019 was finalized. Results: The revised schizophrenia algorithm now consists of 5 stages. At Stage 1, monotherapy with atypical antipsychotics was recommended by expert reviewers as the first-line strategy. At Stage 2, most reviewers recommended the use of typical or atypical antipsychotic drugs not used at Stage 1. At Stage 3, many reviewers agreed with the administration of clozapine. At Stage 4, a combination of clozapine and other agents such as antipsychotics, mood stabilizers, antidepressants, or electroconvulsive therapy was recommended. At Stage 5, most reviewers recommended combined treatment with an antipsychotic other than clozapine; and a mood stabilizer, antidepressant, or electroconvulsive therapy. At any stage, prescribing long-acting injectable antipsychotics at the discretion of the clinician was recommended. Conclusion: Compared with previous versions, the KMAP-SPR 2019 now recommends using clozapine earlier in treatment- refractory schizophrenia. In addition, the use of long-acting injectable antipsychotics is now considered to be available at any stage.
참고문헌 (37)
- Field MJ, "Guidelines for clinical practice: from development to use" (1992), National Academy Press
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
- Buchanan RW, "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
- Barnes TR, "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.567~620 (2011)
- Hasan A, "World federation of societies of biological psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, part 1 : update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
- Galletly C, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders", Aust N Z J Psychiatry, 50, pp.410~472 (2016)
- Moore TA, "The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia : 2006 update", J Clin Psychiatry, 68, pp.1751~1762 (2007)
- National Collaborating Centre for Mental Health(UK), "Psychosis and schizophrenia in adults: treatment and management" (2014), National Institute for Health and Care Excellence(UK)
- Canuso CM, "Paliperidone extended-release : a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania", Expert Opin Pharmacother, 11, pp.2557~2567 (2010)
- Chue P, "A review of paliperidone palmitate", Expert Rev Neurother, 12, pp.1383~1397 (2012)
- Tenjin T, "Profile of blonanserin for the treatment of schizophrenia", Neuropsychiatr Dis Treat, 9, pp.587~594 (2013)
- Salgueiro M, "Long-acting injectable second-generation antipsychotics in first-episode psychosis : a narrative review", Int Clin Psychopharmacol, 34, pp.51~56 (2019)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Jones PB, "Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia : Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study(CUtLASS 1)", Arch Gen Psychiatry, 63, pp.1079~1087 (2006)
- Haddad PM, "Nonadherence with antipsychotic medication in schizophrenia : challenges and management strategies", Patient Relat Outcome Meas, 5, pp.43~62 (2014)
- Strejilevich SA, "Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics", Psychiatry Res, 133, pp.277~280 (2005)
- Kishimoto T, "Relapse prevention in schizophrenia : a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics", Mol Psychiatry, 18, pp.53~66 (2013)
- Suzuki T, "Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation", Psychiatry Res, 197, pp.1~6 (2012)
- Taylor DM, "Augmentation of clozapine with a second antipsychotic-a meta-analysis", Acta Psychiatr Scand, 125, pp.15~24 (2012)
- Assion HJ, "Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial", Pharmacopsychiatry, 41, pp.24~28 (2008)
- Genç Y, "Comparison of clozapineamisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine : a single-blind randomized study", Adv Ther, 24, pp.1~13 (2007)
- Chang JS, "Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia : an 8-week, randomized, doubleblind, placebo-controlled trial", J Clin Psychiatry, 69, pp.720~731 (2008)
- Muscatello MR, "Effect of aripiprazole augmentation of clozapine in schizophrenia : a double-blind, placebo-controlled study", Schizophr Res, 127, pp.93~99 (2011)
- Weiner E, "Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine", Neuropsychopharmacology, 35, pp.2274~2283 (2010)
- Josiassen RC, "Clozapine augmented with risperidone in the treatment of schizophrenia : a randomized, double-blind, placebo-controlled trial", Am J Psychiatry, 162, pp.130~136 (2005)
- Freudenreich O, "Risperidone augmentation for schizophrenia partially responsive to clozapine : a double-blind, placebo-controlled trial", Schizophr Res, 92, pp.90~94 (2007)
- Honer WG, "Clozapine alone versus clozapine and risperidone with refractory schizophrenia", N Engl J Med, 354, pp.472~482 (2006)
- Akdede BB, "A double-blind study of combination of clozapine with risperidone in patients with schizophrenia : effects on cognition", J Clin Psychiatry, 67, pp.1912~1919 (2006)
- Sinclair D, "Treatment resistant schizophrenia : a comprehensive survey of randomised controlled trials", BMC Psychiatry, 14, pp.253~ (2014)
- Iversen TSJ, "Side effect burden of antipsychotic drugs in real life-impact of gender and polypharmacy", Prog Neuropsychopharmacol Biol Psychiatry, 82, pp.263~271 (2018)
- Perkins DO, "Adherence to antipsychotic medications", J Clin Psychiatry, 60(Suppl 21), pp.25~30 (1999)
- Emsley R, "The nature of relapse in schizophrenia", BMC Psychiatry, 13, pp.50~ (2013)
- Stevens GL, "Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia", Early Interv Psychiatry, 10, pp.365~377 (2016)
- Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and metaanalysis", Lancet, 379, pp.2063~2071 (2012)
- Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
- Subotnik KL, "Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial", JAMA Psychiatry, 72, pp.822~829 (2015)